CompletedNot Applicable

Preoperative Toxicological Screening on Perioperative Anesthetic Management

Egypt1,260 participantsStarted 2023-12-01

Plain-language summary

Background: Preoperative substance use is a growing concern in patients undergoing metabolic bariatric surgery (MBS), but its impact on short-term outcomes remains debated. This study evaluated the association between preoperative toxicological screening test (TST) results and perioperative outcomes, including anesthesia requirements, postoperative recovery, complications, and one-year weight loss in patients undergoing MBS. Key Points 1. Preoperative toxicological screening identifies a significant proportion (15.1%) of patients undergoing metabolic bariatric surgery with recent substance use that may not be disclosed through self-reporting. 2. Patients with positive toxicological screening tests require significantly higher anesthesia doses, experience more severe postoperative pain, and have higher rates of complications and readmissions within 30 days. 3. While short-term weight loss outcomes at one year show modest differences between toxicological screening test-positive and negative patients, the perioperative risk profile suggests the need for tailored management strategies for patients with recent substance use.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * adult patients (≥18 years) with obesity who were scheduled to undergo primary MBS, including laparoscopic sleeve gastrectomy (LSG), Roux-en-Y gastric bypass (RYGB), or one-anastomosis gastric bypass (OAGB) * Patient selection followed the 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) guidelines for MBS Exclusion Criteria: * previous bariatric or major abdominal surgery * emergency procedures * chronic pain syndromes * severe psychiatric illness * patient refusal that would impair informed consent or compliance with study protocols * inability to complete follow-up assessments

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

history of specific substance use and /or detected by toxicological screening

Timeframe: within 30 days post operative

Anesthesia-related outcomes included dosages of induction agents (specifically propofol) and perioperative opioid consumption (intraoperative fentanyl dose and postoperative morphine consumption).

Timeframe: within 30 days post operative

Pain assessment

Timeframe: within 30 days post operative

Trial details

NCT IDNCT07100314

SponsorGeneral Committee of Teaching Hospitals and Institutes, Egypt

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2024-05-01

View on ClinicalTrials.gov More Toxicology trials

Plain-language summary

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

history of specific substance use and /or detected by toxicological screening

Timeframe: within 30 days post operative

Anesthesia-related outcomes included dosages of induction agents (specifically propofol) and perioperative opioid consumption (intraoperative fentanyl dose and postoperative morphine consumption).

Timeframe: within 30 days post operative

Pain assessment

Timeframe: within 30 days post operative